Bavarian Nordic A/S (BVNRY)
11.04
-0.12
(-1.03%)
USD |
OTCM |
Sep 25, 16:00
Bavarian Nordic Research and Development Expense (TTM) : 102.03M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 102.03M |
| March 31, 2026 | 121.15M |
| December 31, 2025 | 118.01M |
| September 30, 2025 | 118.79M |
| June 30, 2025 | 136.85M |
| March 31, 2025 | 122.55M |
| December 31, 2024 | 125.21M |
| September 30, 2024 | 160.46M |
| June 30, 2024 | 264.61M |
| March 31, 2024 | 307.93M |
| December 31, 2023 | 323.95M |
| September 30, 2023 | 332.73M |
| June 30, 2023 | 238.40M |
| March 31, 2023 | 191.27M |
| December 31, 2022 | 164.11M |
| September 30, 2022 | 107.18M |
| June 30, 2022 | 70.26M |
| March 31, 2022 | 59.55M |
| December 31, 2021 | 63.53M |
| September 30, 2021 | 65.76M |
| June 30, 2021 | 70.01M |
| March 31, 2021 | 62.83M |
| December 31, 2020 | 52.80M |
| September 30, 2020 | 52.29M |
| June 30, 2020 | 49.82M |
| Date | Value |
|---|---|
| March 31, 2020 | 55.31M |
| December 31, 2019 | 61.35M |
| September 30, 2019 | 60.20M |
| June 30, 2019 | 57.82M |
| March 31, 2019 | 57.85M |
| December 31, 2018 | 61.32M |
| September 30, 2018 | 67.08M |
| June 30, 2018 | 77.63M |
| March 31, 2018 | 75.89M |
| December 31, 2017 | 68.86M |
| September 30, 2017 | 62.02M |
| June 30, 2017 | 54.17M |
| March 31, 2017 | 55.35M |
| December 31, 2016 | 58.53M |
| September 30, 2016 | 56.04M |
| June 30, 2016 | 53.66M |
| March 31, 2016 | 53.40M |
| December 31, 2015 | 55.53M |
| September 30, 2015 | 66.72M |
| June 30, 2015 | 75.46M |
| March 31, 2015 | 79.91M |
| December 31, 2014 | 76.63M |
| September 30, 2014 | 70.39M |
| June 30, 2014 | 66.08M |
| March 31, 2014 | 64.99M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Evaxion AS | 10.27M |
| Genmab A/S | 1.781B |
| Ascendis Pharma A/S | 315.81M |
| Zealand Pharma A/S | 286.45M |
| Agenus, Inc. | 57.69M |